

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT2811073

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	LIQUIDATING TRUST	04/07/2014
RECEIVING PARTY DATA		
Name:	MERCK SHARP & DOHME CORP.	
Street Address:	126 EAST LINCOLN AVENUE	
City:	RAHWAY	
State/Country:	NEW JERSEY	
Postal Code:	07065	
PROPERTY NUMBERS Total: 1		
Property Type	Number	
Application Number:	11820363	
CORRESPONDENCE DATA		
Fax Number:	(732)594-2300	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	732-594-2807	
Email:	US_efs@merck.com	
Correspondent Name:	GLORIA M. FUENTES	
Address Line 1:	126 EAST LINCOLN AVENUE	
Address Line 4:	RAHWAY, NEW JERSEY 07065	
ATTORNEY DOCKET NUMBER:	23750	
NAME OF SUBMITTER:	JILL FILIPPONE	
SIGNATURE:	/Jill Filippone/	
DATE SIGNED:	04/11/2014	
Total Attachments: 4		
source=PATENT ASSIGNMENT LIQUIDATING TRUST AND MSD#page1.tif		
source=PATENT ASSIGNMENT LIQUIDATING TRUST AND MSD#page2.tif		
source=PATENT ASSIGNMENT LIQUIDATING TRUST AND MSD#page3.tif		
source=PATENT ASSIGNMENT LIQUIDATING TRUST AND MSD#page4.tif		

Patent Assignment

THIS PATENT ASSIGNMENT (this "Assignment") is made and entered into as of April 7, 2014 (the "Effective Date"), by and between Tolerx Liquidating Trust ("Assignor"), and Merck Sharp & Dohme Corp. ("Assignee").

WHEREAS, Assignor and Assignee are parties to that certain Asset Purchase Agreement dated as of March 7, 2014 (the "Purchase Agreement"), pursuant to which Assignor has agreed to sell and Assignee has agreed to purchase those United States patents and patent applications and the foreign patents and patent applications (which for the purpose of this Assignment shall be deemed to include certificates of invention and applications for certificates of invention) identified and set forth on Schedule 1 attached hereto (the "Patents"); and

WHEREAS, Assignee wishes to acquire and Assignor wishes to assign all right, title and interest in and to the Patents.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor does hereby sell, assign, transfer and set over to Assignee, the entire right, title and interest in and to the Patents, for the United States and for all foreign countries, including any continuations, divisions, continuations in part, reissues, reexaminations, extensions, renewals, substitutions, registrations, revalidations, supplementary protection certificates and the like of any such Patents or foreign equivalents thereof, and including the subject matter of all claims which may be obtained therefrom for its own use and enjoyment, and for the use and enjoyment of its successors, assigns or other legal representatives, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment and sale had not been made.

Assignor authorizes and requests the Commissioner of Patents and Trademarks, or the equivalent foreign agency, entity or individual, to record Assignee as owner of the Patents, including any continuations, divisions, continuations-in part, reissues, reexaminations extensions, renewals, substitutions, registrations, revalidations, supplementary protection certificates and the like of any such Patents thereof, and to issue any and all letters patent of the United States thereon to Assignee, as assignee of the entire right, title and interest in, to and under the same, for the sole use and enjoyment of Assignee, its successors, assigns or other legal representatives. Assignee shall be responsible for recording this Assignment in all applicable jurisdictions.

[signature page follows]

IN WITNESS WHEREOF, Assignor and Assignee have caused this Assignment to be executed by their duly authorized representatives as of the Effective Date.

Assignor:

TOLERX LIQUIDATING TRUST


By: Marc Weiss
Name: Marc Weiss
Title: President

ACKNOWLEDGEMENT

Country of United States)
) ss :

On this 9th day of April, 2014 personally appeared before me Marc Weiss to me known, and known by me to be the same person described in and who executed the foregoing instrument, and acknowledged that he (she) executed the same, of his (her) own free will for the purpose set forth.

(Seal)



[Signature]
Notary Public

Assignee:

MERCK SHARP & DOHME CORP.

By: [Signature]
Name: Gloria Fuentes
Title: Assistant Managing Counsel, Patents

ACKNOWLEDGEMENT

County of Union)
State New Jersey) ss :
Country of New Jersey)

On this 9th day of April, 2014 personally appeared before me Gloria Fuentes to me known, and known by me to be the same person described in and who executed the foregoing instrument, and acknowledged that he (she) executed the same, of his (her) own free will for the purpose set forth.

(Seal)

[Signature]
Notary Public

JILL M. FILIPPONE
NOTARY PUBLIC OF NEW JERSEY
My Commission Expires March 11, 2018

PATENT

REEL: 032657 FRAME: 0276

Schedule 1

Patent family: ILT3-binding molecules and uses therefor			
<u>Country/Region</u>	<u>Application No. (A)/Patent No. (P)</u>	<u>Filing date (F), earliest priority date (P), and issue date (I)</u>	<u>Status</u>
U.S.	A: 11/471,397 Pub. No: US2007/0041982	F:6/19/06; P:6/17/05 Pub.2/22/07	Pending
Australia	A:2006-261127 P: 2006261127	F:6/19/06 P:6/17/05 I: 7/5/12	Issued
Canada	A: 2611519	F:6/19/06 P: 6/17/05	Pending
Europe	A: 06785268.1	F:6/19/06 P:6/17/05	Pending
Hong Kong	A: 08110530.8	F: 6/19/06 P:6/17/05	Pending
Japan	A: 2008-517229	F: 6/19/06 P:6/17/05	Granted

Patent family: ILT3-binding molecules and uses therefor			
<u>Country/Region</u>	<u>Application No. (A)/Patent No. (P)</u>	<u>Filing date (F),earliest priority date (P), and issue date (I)</u>	<u>Status</u>
U.S.	A: 11/820,363 Pub.No.: US2008/0038260 P: 7,777,008	F: 6/19/07 P: 6/19/06 Pub.: 2/14/08 I: 8/17/10	Issued
U.S. CON1	A: 12/831,156 Pub. No.:2011/0034675	F: 7/6/10 P: 6/19/06 Pub.:2/10/11	Pending
Australia	A: 2007-345745 P: 2007345745	F: 6/19/07 P: 6/19/06 I:5/16/13	Issued
Canada	A: 2655903	F: 6/19/07 P: 6/19/06	Pending
Europe	A: 07872531.4	F: 6/19/07 P:6/19/07	Allowed
Hong Kong	A: 09109088.5	F: 6/19/07 P: 6/19/06	Pending
Japan	A: 2009-526534	F: 6/19/07 P: 6/19/06	Pending

Patent family: Anti-ILT5 antibodies and ILT5-binding antibody fragments			
<u>Country/Region</u>	<u>Application No. (A)/Patent No. (P)</u>	<u>Filing date (F),earliest priority date, and issue date (I)</u>	<u>Status</u>
International PCT	A: PCT/US2011/021939 Pub No: WO2011/091177	F: 1/20/11 P: 1/20/10 Pub: 7/28/11	Pending
Australia	A:2011-207253	F:7/18/12 P:1/20/10	Pending
Canada	A:2787783	F:7/18/12 P:1/20/10	Pending
Europe	A:11735199.9	F:7/18/12 P:1/20/10	Pending
Hong Kong	A:13106359.7	F:5/27/13 P:1/20/10	Pending
U.S.	A:13/574,307 Pub. No.:US2013/0030156	F:7/20/12 P: 1/20/10 Pub:1/31/2013	Pending
Japan	A: 2012-550125	F:7/18/12 P:1/20/10	Pending

Patent family: Immunoregulation by anti-ILT5 antibodies and ILT5-binding antibody fragments			
<u>Country/Region</u>	<u>Application No. (A)/Patent No. (P)</u>	<u>Filing date (F),earliest priority date, and issue date (I)</u>	<u>Status</u>
U.S. Provisional	A:61/296,788	F:1/20/10	Expired
International PCT	A:PCT/US2011/021943 Publication No: WO2011/091181	F: 1/20/11 P: 1/20/10 Publication date: 7/28/11	Expired
Australia	A:2011-207257	F:7/18/12 P:1/20/10	Pending
Canada	A:2787755	F:7/18/12 P:1/20/10	Pending
Europe	A:11735200.5	F:7/18/12 P:1/20/10	Pending
Hong Kong	A:13106360.4	F:5/27/13 P:1/20/13	Pending
U.S.	A:13/574,391 Pub. No.: US2013/0052196	F:7/18/12 P:1/20/10 Pub.:2/28/13	Restriction Requirement received (9/9/13)
Japan	A:2012-550126	F:7/18/12 P:1/20/10	Pending